Diabetes Mellitus Clinical Trial
Official title:
Wheeling to Healing: Does Wheeled Knee Walker Use Improve Wound Healing, Improve Quality of Life and Decrease Risk of Contralateral Ulceration in People With Diabetic Foot Ulcers
NCT number | NCT04257565 |
Other study ID # | Bio1469 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2022 |
Est. completion date | September 30, 2025 |
The increasing incidence of diabetes and high risk of amputation makes prevention and successful treatment of DFU of vital importance. A relatively new device, the wheeled knee walker, allows total offloading of the affected foot and, when compared to traditional walking aids such as crutches and walkers, requires significantly less physical exertion, is easier to use, and affords more stability. Its potential benefit to improve wound healing, impact physical function and quality of life in people with DFU is not yet known. Therefore, the goal of this research is to determine whether providing a wheeled knee walker to people with diabetic foot ulcers improves clinical outcomes and quality of life when compared to usual and customary care.
Status | Recruiting |
Enrollment | 68 |
Est. completion date | September 30, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years old - currently under physician care for a DFU of one foot - willing and able to sign informed consent - cognitively functional - have access to a telephone - weigh no more than 300lbs as this is the weight limitation of the wheeled knee walker - have at least one palpable foot pulse - have a neuropathic plantar DFU corresponding to grade 1A (superficial, not extending to tendon, capsule, or bone) using the University of Texas Diabetic Foot Wound Classification System Exclusion Criteria: - coronary or cerebrovascular disease events within the past six months - uncontrolled, severe medical conditions that place the subject at high risk for adverse events, including but not limited to severe congestive heart failure, angina pectoris, obstructive pulmonary disease - uncontrolled neurologic or psychiatric disorders - active infection - significant ulcers or infections of both lower limbs - those who have been wheelchair dependent prior to ulcer formation - absence of pedal pulse - any condition that would limit the ability to ambulate or stand without pain or discomfort, including but not limited to shortness of breath, fatigue, angina, severe arthritis - medication use that causes impaired balance or judgment - other circumstances at the investigators' and primary care providers' discretion. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Saskatchewan | Saskatoon | Saskatchewan |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan | Saskatchewan Health Research Foundation |
Canada,
Bohannon RW. Normative reference values for the two-minute walk test derived by meta-analysis. J Phys Ther Sci. 2017 Dec;29(12):2224-2227. doi: 10.1589/jpts.29.2224. Epub 2017 Dec 13. — View Citation
Brooks D, Hunter JP, Parsons J, Livsey E, Quirt J, Devlin M. Reliability of the two-minute walk test in individuals with transtibial amputation. Arch Phys Med Rehabil. 2002 Nov;83(11):1562-5. doi: 10.1053/apmr.2002.34600. — View Citation
Jeffcoate WJ, Musgrove AJ, Lincoln NB. Using image J to document healing in ulcers of the foot in diabetes. Int Wound J. 2017 Dec;14(6):1137-1139. doi: 10.1111/iwj.12769. Epub 2017 Jun 13. — View Citation
Lin SJ, Bose NH. Six-minute walk test in persons with transtibial amputation. Arch Phys Med Rehabil. 2008 Dec;89(12):2354-9. doi: 10.1016/j.apmr.2008.05.021. Epub 2008 Nov 1. — View Citation
Reid L, Thomson P, Besemann M, Dudek N. Going places: Does the two-minute walk test predict the six-minute walk test in lower extremity amputees? J Rehabil Med. 2015 Mar;47(3):256-61. doi: 10.2340/16501977-1916. — View Citation
Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia. 1992 Jul;35(7):660-3. doi: 10.1007/BF00400259. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wound Healing | The wound will be measured using Image J, open source digital imaging software developed at the National Institutes of Health (NIH) to measure wound area of the target wound, in mm2 (the largest foot wound if multiple wounds are present). Image J software has been used specifically for the measurement of diabetic foot ulcers with very high inter- and intra-rater reliability (p=0.997 and 0.999 respectively) [1]. The wound will be traced on acetate paper using a fine permanent marker for use in Image J and a standard distance photograph of the wound will be taken to document wound bed characteristics after physician debridement to healthy granulating tissue or healthy bleeding tissue is reached [1, 2]. The physician will record depth at its greatest point using a probe at the time of debridement, assess wound condition (improving, stable, or deteriorating), and the presence or absence of undermining or tunneling. A completely healed wound has complete epithelialization. | 12 Weeks | |
Secondary | Quality of Life: The Diabetic Foot Ulcer Scale (DFS) | The Diabetic Foot Ulcer Scale (DFS) is a specific instrument designed to assess the impact of foot ulcers and their treatment on quality of life in people with Diabetes [3]. The DFS consists of 58 items grouped into 11 domains: leisure, physical health, daily activities, emotions, noncompliance, family, friends, positive attitude, treatment, satisfaction, and financial. The DFS has good internal consistency with adequate test-retest reliability and sensitivity to change in wound status over time indicating its appropriateness for use in clinical trials. DFS Items are scored by the individual using a five item (1-5) scale with higher scores indicating better quality of life. Score will be measured as an aggregate of all 58 items and individually in all 11 domains: Leisure, Physical health, Daily activities, Emotions, Noncompliance, Family, Friends, Treatment, Satisfaction, Positive Attitude, Financial. | 12 weeks | |
Secondary | Risk of ulceration of the sound foot | Risk of ulceration of the sound foot by measuring in-shoe foot force under the sound foot using a LoadSolĀ® Insole (Novel Electronics Inc, St. Paul, MN) while the participant wears their 'usual' footwear. A 0.5 mm thick LoadSolĀ® Insole corresponding to the participants shoe size will be placed between the sock and shoe of the sound foot prior to performing the 2-Minute Walk Test. The embedded grid of contact cells records the normal force between the plantar side of the foot and the shoe during activity. Foot force, in Newtons, will be measured during one minute of footfalls collected from 30 to 90 seconds of the 2-Minute Walk Test. | 12 weeks | |
Secondary | Physical Function | Physical function will be assessed by measuring distance walked (meters) in 2 minutes with Wheeled Knee Walker or Customary device. The 2-Minute Walk Test is a standardized and reliable clinically applicable method for quantifying physical function across and array of health conditions [4-6]. This test is safe in people with peripheral vascular diseases and heart disorders both of which can be precursors to DFU. It has also been proven to be reliable (intraclass coefficient = 0.94) for people with amputation due to diabetes [7]. Participants will be asked to walk in an unobstructed vacant hallway and to cover as much distance as safely possible in two minutes. The participant will wear their prescribed unloading protective footwear and use any prescribed assistive device for testing. They will be followed with a wheelchair in case rest is needed. The distance walked in two minutes will be measured and recorded using a distance measuring wheel. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |